Showing results (41-50 of 72) with videos related to
Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsPontus Tideman, Linda Karlsson, Olof Strandberg, et al.Atherosclerosis|October 26, 2005
Difference in atherosclerosis burden in different nations and continents assessed by coronary artery calciumRaul D Santos, Khurram Nasir, John A Rumberger, et al.Journal of Personalized Medicine|October 28, 2025
Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center StudyMark Monane, Robert M Carlile, Kim G Johnson, et al.Diagnostics (Basel, Switzerland)|August 29, 2024
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid PathologyStephanie M Eastwood, Matthew R Meyer, Kristopher M Kirmess, et al.Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 27, 2025
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemabDoris P Molina-Henry, Rema Raman, Andy Liu, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2026
Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessmentHan-Kyeol Kim, Jae Hoon Lee, Joong-Hyun Chun, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|May 20, 2021
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosisKristopher M Kirmess, Matthew R Meyer, Mary S Holubasch, et al.JAMA|July 28, 2024
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareSebastian Palmqvist, Pontus Tideman, Niklas Mattsson-Carlgren, et al.Diagnostics (Basel, Switzerland)|January 25, 2025
Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey StudyMark Monane, Demetrius M Maraganore, Robert M Carlile, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.Pageof 8